No new moves to compulsory licensing in China, say experts
A recent Reuters report has rung alarm bells about the prospect of compulsory licensing of pharmaceutical products in China. It claims that China is about to follow India, which has recently ordered Bayer to allow a generic version of its cancer…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.